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Abstract
Background: Amyotrophic Lateral Sclerosis (ALS) is a multicausal disease characterized by motor neuron degeneration in
the spinal cord and brain. Cell therapy may be a promising new treatment for this devastating disorder. We recently showed
that a single low dose (10
6 cells) of mononuclear human umbilical cord blood (MNC hUCB) cells administered intravenously
to G93A mice delayed symptom progression and modestly prolonged lifespan. The aim of this pre-clinical translation study
is to optimize the dose of MNC hUCB cells to retard disease progression in G93A mice. Three different doses of MNC hUCB
cells, 10610
6,2 5 610
6 and 50610
6, were administered intravenously into pre-symptomatic G93A mice. Motor function tests
and various assays to determine cell effects were performed on these mice.
Methodology/PrincipalFindings: Our results showed thata celldose of 25610
6 cells significantly increased lifespan of mice by
20–25% and delayed disease progression by 15%. The most beneficial effect on decreasing pro-inflammatory cytokines in the
brain and spinal cord was found in this group of mice. Human Th2 cytokines were found in plasma of mice receiving 25610
6
cells, although prevalent human Th1 cytokines were indicated in mice with 50610
6 cells. High response of splenic cells to
mitogen (PHA) was indicated in mice receiving 25610
6 (mainly) and 10610
6 cells. Significantly increased lymphocytes and
decreased neutrophils in the peripheral blood were found only in animals receiving 25610
6 cells. Stable reduction in microglia
density in both cervical and lumbar spinal cords was also noted in mice administered with 25610
6 cells.
Conclusions/Significance: These results demonstrate that treatment for ALS with an appropriate dose of MNC hUCB cells
may provide a neuroprotective effect for motor neurons through active involvement of these cells in modulating the host
immune inflammatory system response.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurode-
generative disorder characterized by a loss of brain and spinal cord
motor neurons that clinically manifests as a progressive muscular
weakness leading to paralysis and death of patients by respiratory
failure within three to five years of diagnosis [1,2]. Most cases of
ALS are sporadic; the familial (FALS), or genetically linked, form
of ALS represents only 5 to 10 percent of all cases. About 20% of
FALS cases are the result of missense mutations in the Cu/Zn
superoxide dismutase (SOD1) gene on chromosome 21 [3]. Since
the first SOD1 missense mutations were reported, the number of
known mutations has increased to more than 114 (see review, [4]).
Treatments that are available for this disease lack the capacity to
arrest disease progression or repair motor neurons.
Development of an effective treatment is complicated by the
diffuse nature of motor neuron death; cell therapy may be a
promising new treatment for ALS. Cell transplantation theories
are divergent as to whether grafted cells replace dying neurons or
provide a protective environment for neural survival. Motor
neuron replacement through transplantation does not seem an
effective treatment strategy for ALS. Even in animal studies using
neural stem cell treatments, few cells become neurons [5,6] and
there is no evidence that ‘‘new’’ neurons re-innervate muscle.
Bruijn [7] suggest that ‘‘stem cells engineered to secrete growth
factors or other factors required for neuronal survival’’ or to
‘‘stimulate endogenous stem cells in the brain to generate new
neurons’’ may be more feasible for ALS than neural replacement.
Moreover, therapeutic strategies to retard disease progression
‘‘seem to be a more realistic clinical approach as compared with
neuronal replacement’’ [8]. Thus, neuroprotection is more likely
and does not rely on neural cell sources. This suggestion is
supported by a recent study showing that implantation of Sertoli-
enriched testicular cells, ‘‘nurse cells’’ with the ability to produce
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had a significant neuroprotective benefit to vulnerable motor
neurons by possible secretion of neurotrophic factors [9].
Although numerous hypotheses about the etiopathology of this
multifactorial disease have been proposed (see review, [10]),
increasing evidence suggests involvement of the immune/inflam-
matory system [11–15] in ALS pathogenesis. Modulation of
immune/inflammatory effectors in ALS could have a protective
effect for dying motor neurons. Human umbilical cord blood
(hUCB) may be preferable to other cell sources such as bone
marrow or neural stem cells. The hUCB cells are low in
pathogenicity and immune immature. hUCB contains a hetero-
geneous cell population rich in hematopoietic progenitor/stem
cells [16–20], non-hematopoietic cells that can develop into cells of
various tissue lineages [21–24] as well as T cells, B cells and
monocytes. Moreover, it has been shown that cord blood
lymphocytes produce great amounts of the anti-inflammatory
cytokine IL-10 [25]. This plasticity of hUCB cells opens new
approaches for their application in treatment of various disorders
including neurodegenerative diseases (see review, [26,27]). De-
pending upon the pathological microenvironment into which the
hUCB cells are introduced, neuroprotective and/or trophic effects
of these cells appear more likely than neural replacement. In an
animal model of stroke, for example, we showed that hUCB
treatment reduces inflammation and provides neuroprotection
[28,29] by secretion of GDNF or other growth factors [30]. Our
research group [31] and others [32,33] have shown that a single
intravenous (iv) administration of a mononuclear cell (MNC)
fraction from hUCB (MNC hUCB) into pre-symptomatic G93A
SOD1 mice delayed disease symptom progression and extended
lifespan. We demonstrated that ten to twelve weeks after delivery
of a small hUCB cell dose (10
6), the cells were found widely
distributed in the brain, spinal cord, and the peripheral organs
(mainly, in the spleen) [31]. We suggest that hUCB cells may
improve disease outcome through a peripheral immunological
mechanism and may provide a neuroprotective effect for motor
neurons through active involvement of these cells in modulating
the host immune inflammatory system response.
However, the mechanisms underlying the beneficial effect of
hUCB cells for repairing the diseased motor neurons in ALS are still
unclear and the efficiency of these cells in treating ALS has yet to be
determined. The aim of this pre-clinical translation study was to
optimize the dose of hUCB cells to retard disease progression in the
G93A mouse model of ALS. First, we compared the effect of
intravenously transplanted MNC hUCB cells at three different doses
onlifespanand amelioration ofbehavioraldeficitsinthe G93Amice.
Second, we investigated the dose response effect of administered
hUCB cells upon inflammatory induces in G93A mice.
Results
Effect of MNC hUCB cell administration on disease
progression
When MNC hUCB cells at different doses were administered
intravenously into G93A mice at 7–8 wks of age, a significant
increase in survival between cell transplanted and Media-injected or
CsA-injected groups was determined in mice receiving 25610
6 cells
(x
2=4.134, p=0.04, Figure 1, A). Average lifespan of MNC hUCB
administered mice was: 10610
6–128.361.06 days, 25610
6–
140.561.85 days, 50610
6–126.360.96 days compared to
124.561.03 days and 126.961.46 days of Media and CsA mice,
respectively. Some animals (33.3%) from the group receiving
25610
6 cells were alive at 20 weeks of age, when only 21.4% of
the group receiving 10610
6 cells and 7.7% of the group receiving
50610
6 cells survived. Interestingly, G93A mice administered with
25610
6cellssurvived until25wksofage(22wksofage–25%,23wks
of age–16.7%, 25 wks of age–8.3%). Media-injected or CsA-injected
mice survived no longer than 20 weeks of age (Figure 1, B).
At 13–14 weeks of age, symptoms of disease progression appeared
in the experimental G93A mice. The 14 wks old Media-injected,
CsA-injected mice, and micereceiving 50610
6 cells (p,0.05) started
to lose weight while mice administered with 25610
6 and 10610
6
cells maintained body weight until 16 wks of age after which, their
weight began to slowly decrease. At 16 weeks of age, mice receiving
25610
6 cells had significantly (p,0.05) higher body weight
compared to mice administered with 50610
6 cells. Also, mice with
10610
6 cells showed a tendency (p,0.1) to maintain their weight at
this time. At 20 weeks of age, mice that had received 25610
6 cells
better maintained their body weight (28.160.41 g) than other cell
transplant or control groups and significantly (p,0.05) differed from
mice receiving daily CsA (Figure 2, A).
Fourteen weeks of age was a critical time, when Media-injected
and CsA-injected animals began showing signs of deterioration in
extension reflex (Figure 2, B). At this time, mice which had
received 10610
6 cells or 50610
6 cells showed increasing loss of
hindlimb extension vs. control animals. The mice transplanted
with 25610
6 cells showed more instances of hindlimb extension at
16 wks of age (p,0.05) compared to Media or 50610
6 cells groups
of mice and demonstrated hindlimb extension until 20 wks of age
(Figure 2, B). By 20 wks of age, Media and CsA animals had no
extension and exhibited hindlimb paralysis. At the same age, mice
administered with 25610
6 cells better (p,0.01) extended their
hindlimbs vs. mice receiving CsA and 10610
6 cells.
In the rotorod test, motor deficit of Media or CsA mice was
observed as early as 13 wks of age (Figure 2, C). There were no
significant differences between mice receiving 10610
6 cells,
50610
6 cells, Media, and CsA groups in latency at this time. At
13–14 wks of age, mice administered with 25610
6 cells performed
best in the rotorod test (14 wks of age: latency-133.365.32 sec)
compared with another cell treated animals (14 wks of age:
10610
6 cells [latency-107.265.72 sec], 50610
6 cells [latency-
87.366.61 sec]) and had significantly (p,0.05) longer latency
compared to Media mice. Media or CsA mice were not able to
perform the rotorod test at 18 wks of age, although mice with
10610
6 or 50610
6 cell administrations still achieved this
performance until 19 wks of age. Animals receiving 25610
6 cells
stayed on the rotorod with high latency at 20 wks of age,
significantly better than mice administered with CsA (p,0.05) or
10610
6 cells (p,0.01) (Figure 2, C). These tested mice (33.3% of
which still survived at this time) exhibited partial dysfunction of
their hindlimbs but could still perform this test.
Effect of MNC hUCB cell administration on cytokine
profile
To evaluate the effect of administered MNC hUCB cells at
different doses on neuroinflammatory processes that occur in ALS,
we used the RNase protection assay (RPA) to determine the
mRNA expression of proinflammatory cytokines. Our results
showed significantly higher expression of IL-1 a mRNA in the
lumbar spinal cord of Media (p,0.05), CsA (p,0.05), MNC
hUCB 10610
6 (p,0.05), and MNC hUCB 50610
6 (p,0.05)
mouse groups compared with those in control hTgn mice
(Figure 3). No differences were observed between mice receiving
10610
6 or 50610
6 cells and Media- or CsA-injected. However,
mice administered with 25610
6 cells tended to decreased IL-1 a
expression in the lumbar spinal cord (p=0.1) compared to CsA-
injected animals. Although, the expression of IL-1 a mRNA in the
brainstem did not significantly differ between cell-treated and non-
HUCB Cell Dose in ALS
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cytokine was observed in mice received 10610
6 or 25610
6 cells.
Interestingly, there were no differences in IL-1 a mRNA
expression in motor cortex between cell-treated, non-treated
G93A mice and control hTgn or C57BL/6 mice (Figure 3).
Similar to results of IL-1 a mRNA expression in the lumbar
spinal cord, IL-1 b mRNA was significantly higher in mice
receiving Media (p,0.01), CsA (p,0.05), MNC hUCB 10610
6
(p,0.05), and MNC hUCB 50610
6 (p,0.01) compared to hTgn
mice (Figure 3). The tendency to decreased IL-1 b mRNA in the
lumbar spinal cord was found in mice administered with 25610
6
MNC hUCB cell dose (p=0.1) compared with those in Media-
injected G93A mice. In the brainstem, significant increase of IL-1
b mRNA expression was detected in Media (p,0.05), CsA
(p,0.001), MNC hUCB 50610
6 (p,0.05) vs. control hTgn or
C57BL/6 mice. There were no differences in IL-1 b mRNA
expression between G93A mice treated with different cell doses.
However, in motor cortex, mice receiving 25610
6 MNC hUCB
cells showed significant decrease of IL-1 b mRNA expression
(p,0.05) compared to CsA-injected mice.
The expression of TNF a mRNA in the lumbar spinal cord was
only significantly higher in mice administered with MNC hUCB
10610
6 cells compared to hTgn (p,0.05) or C57BL/6 (p,0.05)
mice. Decrease of TNF a mRNA was noticed in MNC hUCB
25610
6 (p,0.05) compared with those in MNC hUCB 10610
6
mouse group(Figure 3). There were no differences in TNF a mRNA
expression in the brainstem between cell-treated and non-treated
G93A mice;allshowinghighcytokineexpressionvs.controlhTgn or
C57BL/6 mice: Media (p,0.01), CsA (p,0.001), MNC hUCB
10610
6(p,0.05),MNChUCB25610
6(p,0.05), and MNC hUCB
50610
6 (p,0.01). A similar effect of TNF a mRNA expression
between cell-treated and non-treated micewas detected inthe motor
Figure 1. Effect of MNC hUCB cell administration on lifespan of G93A mice. A) Kaplan-Meier survival curves for G93A mice receiving
10610
6,2 5 610
6, and 50610
6 MNC hUCB cells. Control groups were Media and CsA. Significant (four pointed star) increase in survival between cell
transplanted and Media-injected or CsA-injected groups was determined in mice receiving 25610
6 cells (x
2=4.134, p=0.04). B) Some animals
(33.3%) from the group receiving 25610
6 cells were alive at 20 wks of age, when only 21.4% of the group receiving 10610
6 cells and 7.7% of the
group receiving 50610
6 cells survived. G93A mice administered with 25610
6 cells survived until 25 wks of age (22 wks of age–25%, 23 wks of age–
16.7%, 25 wks of age–8.3%). Media-injected or CsA-injected mice survived no longer than 20 weeks of age.
doi:10.1371/journal.pone.0002494.g001
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G93A mice vs. control hTgn or C57BL/6 mice.
Results on the expression of TNF b mRNA in the lumbar spinal
cord showed that only mice receiving 10610
6 (p,0.01), 25610
6
(p,0.05), and 50610
6 (p,0.05) MNC hUCB cells significantly
increased this cytokine compared to hTgn control mice (Figure 3).
No differences in TNF b mRNA expression were found between
mice treated with different cell doses. Interestingly, G93A mice
receiving CsA showed similar cytokine expression to C57BL/6
mice. In the brainstem and motor cortex, TNF b mRNA
expressions were not significantly different between cell-treated
and non-treated G93A or control hTgn and C57BL/6 mice.
The expression of IL-1 a mRNA in the spleen showed a
tendency towards decreased levels of this cytokine only in mice
receiving 10610
6 cells (p,0.1) compared to Media-injected
animals (Figure 4). There were no differences in IL-1 b mRNA
expression between G93A mice treated with different cell doses
and control animals. However, TNF a m RNA expression was
significantly decreased in the spleens of mice with 10610
6
(p,0.05), 25610
6 (p,0.05), and 50610
6 (p,0.05) MNC hUCB
cell treatments vs. CsA-injected animals. Interestingly, the
expression of TNF b mRNA was significantly reduced in mice
receiving 10610
6 cells compared to either hTgn (p,0.01) or CsA
(p,0.05) mice; as a tendency towards a decrease in this cytokine
expression was found in mice with 50610
6 (p=0.0571) cell dose
vs. CsA-injected mice. Notably, the highest TNF a m RNA and
TNF b mRNA expressions were detected in the spleens of mice
receiving daily CsA injections (Figure 4). Surprisingly, mice with
25610
6 cell treatment also showed high expression of TNF b
mRNA similar to mice with CsA. Although, there were no
statistical differences in IL-2 mRNA and IL-10 m RNA
expressions between G93A mice treated with different cell doses
and control animals (Media, CsA, hTgn, C57), mice receiving
25610
6 MNC hUCB cells tended towards decreased IL-2 mRNA
and increased IL-10 mRNA expressions in the spleen.
To address the question of how transplanted cells provide their
beneficial effect, we investigated human Th1 and Th2 cytokines in
plasma of G93A mice transplanted with different MNC hUCB cell
doses using a microarray assay. Results showed that 50% of mice
receiving 25610
6 cells showed evidence of human IL-4 and IL-13
(Th2) (Figure 5). In 62.5% of mice with 50610
6 cell treatment, all
human cytokines were detected except for IL-5, IL-5, and IL-10
(Th2). Interestingly, IL-4 and IL-13 cytokine concentrations in
these mice were lower than those in mice receiving 25610
6 cells.
There were no human cytokines detected in mice treated with
10610
6 cell dose. The hUCB plasmas themselves, mostly
contained Th2 cytokines (IL-4, IL-10, and IL-13). Although a
higher amount of IL-10 was found in hUCB plasma, IFN-gamma
(Th1) was also indicated.
Effect of MNC hUCB cell administration on splenocyte
proliferation
With evidence that cells colonized the spleen, we investigated
the immune responsiveness of splenocytes in treated G93A mice
with different MNC hUCB cell doses. The spleen weights in G93A
Media mice slightly increase compared to control hTgn or
C57BL/6 mice, whereas splenic weight in G93A mice receiving
CsA was less (Figure 6, A). A marked increase of spleen mass was
found in mice treated with 10610
6 or 50610
6 MNC hUCB cell
doses, however, high variability in measurements were detected
within groups. In mice receiving 25610
6 cells, spleen mass was less
than other cell treated groups and similar to control animals.
However, splenocyte proliferation stimulated by PHA was not
detected in Media or CsA-treated mice compared to control hTgn
or C57BL/6 mice. Surprisingly, reaction to mitogen also was not
found in mice receiving 50610
6 MNC cells (Figure 6, B).
Significant immune response to mitogen (i.e. increased splenic
cell proliferation) was found in G93A mice treated with 25610
6
(mainly) and 10610
6 MNC hUCB cells.
Figure 2. Characteristics of disease progression in G93A mice.
A) body weight, B) extension reflex, and C) rotorod test of G93A mice
administered with three different cell doses, Media-injected, CsA-
injected and control hTgn mice. At 16 wks and 20 wks of age, mice
receiving 25610
6 cells better maintained their body weight, extended
hindlimbs, and stayed longer on rotorod than other cell transplant or
control groups. The four pointed stars in A, B, and C indicates
significant difference: in body weight–16 wks of age: 25610
6 cells vs.
50610
6 cells (p,0.05); 20 wks of age: 25610
6 cells vs. CsA (p,0.05); in
extension reflex–25610
6 cells vs. Media or 50610
6 cells (p,0.05); 20 wks
of age-25610
6 cells vs. CsA or 10610
6 cells (p,0. 01); in rotorod–14 wks
of age: 25610
6 cells vs. Media (p,0.05); in 20 wks of age-25610
6 cells
vs. CsA (p,0.05) or 10610
6 cells (p, 0.01).
doi:10.1371/journal.pone.0002494.g002
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response in the peripheral blood
For identification of the MNC hUCB cells in the peripheral
blood, immunohistochemical staining using human specific
antibody (HuNu) was performed. Blood test results showed many
transplanted MNC hUCB cells in animals receiving all three cell
doses (Figure 7, A). The Complete Blood Count (CBC) in the
peripheral blood of G93A mice receiving different MNC hUCB
cell doses showed no differences in red blood cell (RBC) count,
levels of hemoglobin (Hb) and hematocrit (Htc) compared to
Media, CsA, hTgn and C57 BL/6 mice. The RBC average in cell
Figure 3. Cytokine profile in the lumbar spinal cord, brainstem, and motor cortex of G93A mice administered with different MNC
hUCB cell doses. The RNase protection assay was used to determine the mRNA expression of proinflammatory cytokines IL-1 a, IL-1 b, TNF a, and
TNF b in the lumbar spinal cord (left column), brainstem (center column), and motor cortex (right column) of G93A mice administered with different
MNC hUCB cell doses. Control groups were Media, CsA, hTgn, and C57BL/6 mice. The mRNA expression presented as the optical density (OD) values
obtained from each band normalizing against the OD obtained from the L32, a house-keeping gene, band. Lines indicated significant differences
(p,0.001, p,0.01, and p,0.05) between mouse groups (see Results).
doi:10.1371/journal.pone.0002494.g003
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6 cells–8.05, 25610
6 cells–8.49,
50610
6 cells-8.05 vs. 8.24 (Media), 8.20 (CsA), 7.52 (hTgn), and
7.59610
6/mL (C57BL/6) mice. The Hb and Htc amounts were
similar in all animal groups averaging 11.58-12-46 g/dL and 32.69–
35.63 %, respectively. However, white blood cell (WBC) counts
demonstrated significantly reduced numbers of WBC cells in Media
(p,0.05) and CsA-injected (p,0.05) G93A mice compared to
C57BL/6 mice (Figure 7, B). In contrast, all mice treated with MNC
hUCB cells showed slightly increased WBC counts. WBC
differential analysis showed a low percentage of neutrophils in
control hTgn and C57BL/6 mice averaging 12.6063.11 and
22.1465.62, respectively (Figure 7, C). A significant increase of
neutrophils (almost 4–5 fold) was found in Media (54.4068.46,
p,0.01) and CsA (65.5765.09, p,0.001) vs. hTgn or C57BL/6
mice. Decreased neutrophils in the G93A mice administered with
MNChUCBcellsweremostsignificantlypronouncedinthe 25610
6
cell group (p,0.05) compared to CsA-injected mice. The lympho-
cyte percentage was significantly decreased in Media (p,0.001) and
CsA (p,0.001) groups compared to those in hTgn. However,
lymphocyte percentages in mice treated with 10610
6 and 50610
6
cells did not differ from Media mice and showed a slight increase
when compared to CsA animals. In mice receiving 25610
6 cells, a
significant increase of lymphocytes (p,0.05) vs. CsA-injected mice
was determined (Figure 7, C).
Effect of MNC hUCB cell administration on microglia in
the spinal cord
Microglial cell density in the ventral cervical and lumbar horns
of all G93A, treated with different cell doses or non-treated
(Media, CsA), mice was significantly (p,0.001) increased vs.
C57BL/6 animals (Figure 8, A, B). However, cell density in mice
injected with CsA was significantly lower in the cervical spinal
cord compared to Media (p,0.01) and 10610
6 cells (p,0.001)
Figure 4. Cytokine profile in the spleen of G93A mice administered with different MNC hUCB cell doses. The RNase protection assay
was used to determine the mRNA expression of proinflammatory cytokines (IL-1 a, IL-1 b, TNF a, TNF b, and IL-2) and anti-inflammatory cytokine IL-10
in the spleen of G93A mice administered with different MNC hUCB cell doses. Control groups were Media, CsA, hTgn, and C57BL/6 mice. The mRNA
expression presented as the optical density (OD) values obtained from each band normalizing against the OD obtained from the L32, a house-
keeping gene, band. Lines indicated significant differences (p,0.001, p,0.01, and p,0.05) between mouse groups (see Results).
doi:10.1371/journal.pone.0002494.g004
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(p,0,001), 25610
6 cells (p,0.01) and 50610
6 cells (p,0.001)
groups. In the cervical spinal cord, mice receiving 10610
6 MNC
hUCB cells showed significantly (p,0.001) higher microglial cell
density vs. mice with 25610
6 and 50610
6 cell doses (Figure 8, A).
Animals from these last two groups had microglia of similar
appearance and significantly (p,0.01 and p,0.05, respectively)
reduced numbers of cells compared to the Media group. In the
lumbar spinal cord, a significant decrease of microglial cell density
was observed in mice receiving 10610
6 and 25610
6 cells vs.
Media mice (Figure 8, B). Moreover, density of microglial cells in
mice receiving cell transplants correlated positively with cell
dosage. Mice with 10610
6 cells had a significantly lower density of
microglia than mice administered with 25610
6 (p,0.05) and
50610
6 (p,0.001) cell doses and cell density was significantly
(p,0.05) reduced in mice with 25610
6 cells vs. 50610
6 cells
(Figure 8, B).
Immunohistochemical analysis of administered MNC
hUCB cells in vivo
Immunohistochemically, the MNC hUCB cells, identified by
human-specific marker (HuNu), were widely distributed in the
cervical and lumbar spinal cord of G93A mice treated with
different cell doses. The immunophenotype of transplanted cells
was verified by double-staining for Nestin.
In the cervical (Figure 9) and lumbar (Figure 10) spinal cord,
targets of motor neuron degeneration in ALS, most cells
congregated in, or some distance away from, the blood vessels.
Some of the administered cells were found in the parenchyma of
the gray matter and expressed Nestin. Notably, administered
MNC hUCB cells in the cervical or lumbar spinal cord appeared
in several morphologically distinct types with rounded or oval
shapes. The HuNu positive MNC hUCB cells were also found in
the cervical/lumbar central canal and in white matter of the
lumbar spinal cord.
Discussion
ALS is a multifactor disease characterized by motor neuron
degeneration in the brain and spinal cord. Development of an
effective treatment is complicated by multiple locations of motor
neuron death; cell therapy may be a promising new treatment for
ALS. Numerous reports showing the plasticity of hUCB cells in
both in vitro and in vivo opens new approaches for their application
in treatment of various disorders including neurodegenerative
diseases (see review, [26,27]). In the present study, we focused on
optimization of the MNC hUCB cell dose for treatment of ALS
and possible mechanisms of beneficial cell interventions.
The major findings in our study were: 1) administration of the
MNC hUCB cells at three different doses (10610
6,2 5 610
6, and
50610
6 cells) into the systemic circulation of G93A mice showed
that that a cell dose of 25610
6 cells significantly increased lifespan
of mice by 20–25% and delayed disease progression by at least
15%; 2) the most beneficial effect on decreasing pro-inflammatory
cytokines in the brain and spinal cord was found in mice with
25610
6 cells; 3) human Th2 cytokines were found in plasma of
mice receiving 25610
6 cells, although prevalent human Th1
cytokines were indicated in mice with 50610
6 cells; 4) high
response of splenic cells to mitogen (PHA) was indicated in mice
receiving 25610
6 (mainly) and 10610
6 cells; 5) significantly
increased lymphocytes and decreased neutrophils in the peripheral
blood were found only in animals receiving 25610
6 cells; 6) stable
reduction in microglia density in both cervical and lumbar spinal
cords was noted in mice administered with 25610
6 cells; 7) MNC
hUCB cells expressing Nestin were found in the cervical and
lumbar spinal cords of all mice receiving MNC hUCB cells.
Thus, our results show that the optimal MNC hUCB cell dose
for treatment of G93A SOD1 mice is 25610
6 cells, which
significantly increased lifespan of mice and delayed disease
progression. Over thirty three percent of mice from this group
were alive at 20 wks of age, when only 21.4% of the group
receiving 10610
6 cells and 7.7% of the group receiving 50610
6
Figure 5. Human Th1/Th2 cytokines in plasma from G93A mice administered with different MNC hUCB cell doses. FAST Quant
microspot assay for human Th1/Th2 Cytokines (IL-1 b, TNF a, INF c, IL-2, IL-4, IL-5, IL-6, IL10, and IL-13) in plasma from G93A mice receiving three
different cell doses was performed by Schleicher & Schuell BioScience, Inc. (Keene, NH, USA). Plasma samples from hUCB (n=10) were used as
controls. Quantitative results of cytokines were presented as pg/mL. The 50% of mice receiving 25610
6 cells showed evidence of human IL-4 and IL-
13 (Th2). In 62.5% of mice with 50610
6 cell treatment, all human cytokines were detected except for IL-5, IL-5, and IL-10 (Th2). There were no human
cytokines detected in mice treated with 10610
6 cell dose. The hUCB plasmas themselves, mostly contained Th2 cytokines (IL-4, IL-10, and IL-13).
doi:10.1371/journal.pone.0002494.g005
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mice survived no longer than 20 weeks of age. Even this modest
percentage (33.3) of surviving G93A mice, ‘‘high copy’’ mice
carrying ,25 copies of mutated gene, which received 25610
6
cells, proves the effectiveness of this cell dose. Along with survival,
importantly, disease progression was delayed and motor ability
retained in these mice. Compared to mice receiving other cell
doses and Media-injected or CsA-injected mice, this transplant
mouse group showed superior motor function, limited only by a
slight decrease in body weight and these mice kept some
movement ability until late stage disease. Additionally, a modest
positive effect on motor function was observed in mice receiving
10610
6 cells.
The first report by Ende et al. [32]) on a possible treatment for
ALS with MNC hUCB cells showed that intravenous administra-
tion of a high dose (35610
6 cells) of MNC hUCB substantially
increased the lifespan of mice [32,33]. The hUCB cells were
transplanted into irradiated mice and the authors [32] suggest that
these cells may possibly ‘‘provide enhanced hematopoietic
reconstitution of the irradiated hosts own stem cells.’’ While the
survival data was impressive, the investigators did not examine
motor function in these animals or determine the underlying
mechanism(s). Presently, our most beneficial cell dose (25610
6
cells) is lower than described above and our G93A mice were non-
irradiated. Another cell dose (10610
6 cells) we investigated had
only modest therapeutic effect in G93A mice and results were
similar to the effects of low (10
6 cells) cell administration described
in our previous study [31]. There likely is a threshold dosage, that
these low doses did not attain necessary to provide significant
neuroprotection for motor neurons. Surprisingly, administration of
the highest MNC hUCB cell dose (50610
6 cells) into G93A mice
did not show a curative effect; only 38% of these mice survived at
18 wks of age compared to 71% (10610
6 cells) and 83% (25610
6
cells) at this age. It is possible that the 50610
6 cell dose is high
enough to induce immunological ‘‘conflict’’, similar to the effect
seen in graft-versus-host disease. Additionally, a bell-shaped dose
response curve balancing neuroprotective and potentially toxic
effects might explain the observed effect of the highest cell dose, as
is commonly seen in pharmaceutical drug testing.
In ALS, in the brainstem and spinal cord of both patient and
animal models, increasingly large numbers of activated microglia
and astrocytes, IgG, and T lymphocytes [13,34–36] may be
capable of secreting the numerous cytokines playing key roles in
the inflammatory reaction. The increase of macrophage-cytokines
such as interleukin (IL) 1alpha, IL 1beta and IL 1RA, the pro-
inflammatory enzyme cyclooxygenase type 2 (Cox-2) [35,37], and
up-regulation of the tumor necrosis factor-alpha (TNF-alpha) gene
[38,39] makes them likely candidates for inflammatory effectors.
Interestingly, T-cell derived cytokines (lymphokines) including IL
2, IL 3, and IL 4 are not elevated in G93A mice even at late stages
of disease, which led to the suggestion that ‘‘lymphocyte
contributions to cytokine expression in ALS are likely minor’’ [38].
Results of our current study showed that expression of
proinflammatory cytokines in the lumbar spinal cord, brainstem
and motor cortex was structurally variable in G93A mice of both
Media and CsA-injected groups. Significant increases of IL-1 a,
IL-1 b, TNF a, and TNF b were mostly detected in the lumbar
spinal cord and brainstem of these mice compared to control hTgn
or C57BL/6 mice. Cytokine measurements in mice receiving
10610
6 and 50610
6 MNC hUCB cells were identical with Media
or CsA-injected mice. In contrast, a tendency to decreased IL-1 a
and IL-1 b mRNA expressions in the lumbar spinal cord was
found in mice administered with 25610
6 MNC hUCB cells.
Importantly, these mice showed a significant decrease of TNF a
mRNA in the lumbar spinal cord compared to mice receiving
10610
6 MNC hUCB cells. Significantly decreased IL-1 b mRNA
expression in motor cortex was also detected in mice with 25610
6
MNC hUCB cell dose compared with those in CsA-injected mice.
In the spleen, significant decreases of IL-1 a and TNF b were
mostly were found in mice receiving 10610
6 MNC hUCB cells
and all mice treated with different cell doses significantly reduced
expression of TNF a mRNA compared to CsA group. Addition-
ally, although mice treated with 25610
6 cells had high variability
Figure 6. The immune response of splenic cells to a mitogen,
phytohemagglutinin (PHA), in G93A mice treated with differ-
ent doses of MNC hUCB cells. A) The spleen weights in Media mice
slightly increase compared to control hTgn or C57BL/6 mice, whereas
splenic weight in G93A mice receiving CsA was less. A marked increase
of spleen mass was found in mice treated with 10610
6 or 50610
6 MNC
hUCB cell doses, however, high variability in measurements were
detected within groups. In mice receiving 25610
6 cells, spleen mass
was less than other cell treated groups and similar to control animals.
B) Index stimulation reflects the ratio between induced PHA
proliferation and spontaneous division of splenocytes. There was no
splenocyte proliferation found in the Media or CsA injected G93A mice
compared to the control hTgn. The mice receiving 506106 MNC hUCB
cells also did not respond to the mitogen. There was a significant
increase in splenic cell proliferation of the mice treated with 25610
6
(mainly) and 10610
6 MNC hUCB cells. The highest amounts of
proliferation were found in hUCB and C57BL/6 animals used as controls.
*p,0.05 and ** p,0.01.
doi:10.1371/journal.pone.0002494.g006
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hUCB cells were found in the peripheral blood of mice receiving all three cell doses (A-10610
6, B-25610
6, C-50610
6 cells). Administered human cells
were verified by anti-human nuclei staining (green, asterisks). The nuclei in a, b, and c are stained with DAPI, same images as A, B, and C. Scale bar:
A-c is 25 mm. B) White blood cell (WBC) counts demonstrated significantly reduced numbers of WBC cells in Media (p,0.05) and CsA-injected
(p,0.05) G93A mice compared to C57BL/6 mice. All mice treated with MNC hUCB cells showed slightly increased WBC counts. C) WBC differential
analysis showed a low percentage of neutrophils in control hTgn and C57BL/6 mice. A significant increase of neutrophils (almost 4–5 fold) was found
in Media (p,0.01) and CsA (p,0.001) vs. hTgn or C57BL/6 mice. Decreased neutrophils in the G93A mice administered with MNC hUCB cells were
most significantly pronounced in the 25610
6 cell group (p,0.05) compared to CsA-injected mice. The lymphocyte percentage was significantly
decreased in Media (p,0.001) and CsA (p,0.001) groups vs. hTgn. Lymphocyte percentages in mice treated with 10610
6 and 50610
6 cells did not
differ from Media mice. In mice receiving 25610
6 cells, a significant increase of lymphocytes (p,0.05) vs. CsA-injected mice was determined. Lines
indicated significant differences between mouse groups.
doi:10.1371/journal.pone.0002494.g007
HUCB Cell Dose in ALS
PLoS ONE | www.plosone.org 9 June 2008 | Volume 3 | Issue 6 | e2494in IL-2 and IL-10 mRNA expressions in the spleen, they markedly
decreased and increased these cytokines respectively.
Thus, the most beneficial effect on decreasing proinflammatory
cytokines expression in the brain and spinal cord was noticed in
G93A mice administered with 25610
6 MNC hUCB cells and this
effect was observed mainly through inhibition of IL-1 a and IL-1 b
mRNA expressions. Since proinflammatory cytokines may be
indirect mediators for glial cells’ contribution to motoneuron
death, the decrease of these macrophage-cytokines might be due to
a reduction of activated microglia and astrocytes by administration
of the 25610
6 MNC hUCB cells. Also, examination of glutamate
concentration will be important to show therapeutic effect of
MNC hUCB cells, and will be addressed in a future study. In the
periphery (spleen), decreases in proinflammatory cytokines
expression (IL-1 a and TNF b) were detected in mice with
10610
6 MNC hUCB cell dose and reductions of TNF a mRNA
expression were seen in mouse groups with 10610
6 and 25610
6
cell doses. However, mice receiving 25610
6 cells showed a
tendency to increased expression of IL-10 mRNA. These results
were confirmed by findings of human Th1/Th2 cytokines in
plasma of G93A mice treated with different cell doses. The Th2
cytokines were found in mice receiving 25610
6 cells, whereas
prevalent Th1 cytokines were indicated in mice with 50610
6 cells.
Another finding in our present study was significant immune
response to mitogen (i.e. increased splenic cell proliferation) found
in G93A mice treated with 25610
6 (mainly) and 10610
6 cells,
likely due to immunological tolerance and/or active involvement
of grafted MNC hUCB cells in the host immune response. Non-
responsiveness of splenocytes to mitogen in Media, CsA, and
50610
6 cell treated mice might be due to their dysfunctional
lymphocytes, possibly indicating deficient immune response in
these mice. In the case of the highest cell dose administration
(50610
6 cells), immune ‘‘conflict’’ might occur between the high
dose of introduced MNC hUCB cells and the host immune system.
Previously we demonstrated severe lymphopenia accompanied
by spontaneous autorosette formation in G93A mice at terminal
stage of disease [40]. Since transplanted MNC hUCB cells were
found in the peripheral blood of animals receiving all three cell
doses, white blood cell counts showed a slight increase in these
groups compared with non-treated control group mice. However,
the white blood cell differential counts demonstrated that
significantly increased lymphocytes and decreased neutrophils
were found only in animals receiving 25610
6 MNC hUCB cells. It
is possible that restoration of the lymphoid system in G93A mice
by administration of this particular cell dose may have elevated the
immune ‘‘defense’’ system and inhibited the inflammatory
response.
Supporting this working hypothesis, our results on microglia
density in the cervical/lumbar spinal cords showed that the most
beneficial cell reduction was observed in mice receiving 25610
6
and 50610
6 cells doses in the cervical segments, whereas mice
with 10610
6 and 25610
6 cell doses mostly reduced cell density in
the lumbar spinal cord. However, stable reduction in appearance
of microglia in both cervical and lumbar spinal cords was noted in
mice administered with 25610
6 cells. Interestingly, animals
injected with CsA also showed significant decreases of microglia
vs. control Media G93A mice; this indication that the immuno-
suppressive drug itself might also reduce neuroinflammation needs
future investigation.
A necessary step in confirming the utility of any proposed
treatment for ALS is analysis of surviving spinal motor neurons.
However, the present study examined dosage effects of MNC
hUCB cells on lifespan and motor function of ALS mice. Since all
animals remained in the study until end-stage of disease, typically a
result of cumulative motor neuron death, analysis of motor neuron
death in our study is likely to be uninformative. A histological
analysis of surviving spinal motor neurons seems more appropri-
ately performed on mice euthanized at regular intervals after cell
treatment. Such an analysis will be performed in the near future to
confirm the effectiveness of our cell therapy.
Thus, results of our pre-clinical study indicate that MNC hUCB
cells may have therapeutic potential in the treatment of ALS,
providing neuroprotection of motor neurons by inhibiting various
immune inflammatory effectors. Although the optimal beneficial
Figure 8. Effect of MNC hUCB cell administration on microglial
cell density in the spinal cord of G93A mice. Microglial cell density
in the ventral cervical (A) and lumbar (B) horns of all G93A, treated with
different cell doses or non-treated (Media, CsA), mice was significantly
(p,0.001) increased vs. C57BL/6 animals. Cell density in mice injected
with CsA was significantly lower in the cervical spinal cord compared to
Media (p,0.01) and 10610
6 cells (p,0.001) groups of mice and in the
lumbar spinal cord compared to Media (p,0.001), 25610
6 cells
(p,0.01) and 50610
6 cells (p,0.001) groups. A) In the cervical spinal
cord, mice receiving 10610
6 MNC hUCB cells showed significantly
(p,0.001) higher microglial cell density vs. mice with 25610
6 and
50610
6 cell doses. Animals from these last two groups had microglia of
similar appearance and significantly (p,0.01 and p,0.05, respectively)
reduced numbers of cells compared to the Media group. B) In the
lumbar spinal cord, a significant decrease of microglial cell density was
observed in mice receiving 10610
6 and 25610
6 cells vs. Media mice.
Density of microglial cells in mice receiving cell transplants correlated
positively with cell dosage. Mice with 10610
6 cells had a significantly
lower density of microglia than mice administered with 25610
6
(p,0.05) and 50610
6 (p,0.001) cell doses and cell density was
significantly (p,0.05) reduced in mice with 25610
6 cells vs. 50610
6
cells. Lines indicated significant differences between mouse groups.
doi:10.1371/journal.pone.0002494.g008
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PLoS ONE | www.plosone.org 10 June 2008 | Volume 3 | Issue 6 | e2494Figure 9. Immunochistochemical staining of MNC hUCB cells in the cervical spinal cord of G93A mice administered with different
cell doses. MNC hUCB cells were found in the cervical spinal cord of mice receiving A) 10610
6; B), C) 25610
6; and D), E) 50610
6 cells by anti-
human nuclei staining (green, asterisks). Merged images are with DAPI. Some a), b), c), d), and e) MNC hUCB cells were Nestin positive (red,
asterisks). Cells in images a, b, c, d, and e are same in images A, B, C, D, E. cc–central canal. Scale bar: A–e is 25 mm.
doi:10.1371/journal.pone.0002494.g009
Figure 10. Immunochistochemical staining of MNC hUCB cells in the lumbar spinal cord of G93A mice administered with different
cell doses. MNC hUCB cells were found in the lumbar spinal cord of mice receiving A), B) 10610
6; C), D) 25610
6; and E), F) 50610
6 cells by anti-
human nuclei staining (green, asterisks). Merged images are with DAPI. Some a), b), c), d), e), f) MNC hUCB cells expressed Nestin (red, asterisks).
Cells in images a, b, c, d, e, f are same in images A, B, C, D, E, F. Scale bar: A–e is 25 mm.
doi:10.1371/journal.pone.0002494.g010
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tions of smaller cell doses, an approach we plan to take for our
next study. Additionally, since our study only investigated cells
administered into pre-symptomatic G93A mice, future investiga-
tions should determine effects of cell transplants performed at
different stages of disease.
Materials and Methods
Animals
All described procedures were approved by the Institutional
Animal Care and Use Committee at USF and conducted in
compliance with the Guide for the Care and Use of Laboratory Animals.
Transgenic male mice B6SJL-TgN (SOD1-G93A) 1GUR (G93A;
obtained from Jackson Laboratories, Bar Harbor, MA, USA),
over-expressing human SOD1, carrying the Gly93RAla muta-
tion, were used. The G93A mice randomly received MNC hUCB
cells at different doses: 10610
6 (n=14), 25610
6 (n=12) and
50610
6 (n=13) into the jugular vein at 7–8 weeks of age. There
were four control groups: G93A Media-injected (n=10), G93A
Cyclosporine A (CsA)-injected (n=10), C57BL/6 (n=9) and
transgenic mice (BL6/SJL) carrying the normal allele for SOD1
gene (n=5, hTgn). All mice were maintained on a 12:12 h
dark:light cycle (light on at 06:00 hours). Room temperature was
23uC. Food and water were available ad libitum.
Preparation of MNC hUCB cells and transplantation
procedure
Cryopreserved MNC hUCB cells (Saneron CCEL Therapeutics
Inc., Tampa, FL) were thawed rapidly at 37uC then transferred
slowly with a pipette into a 15-ml centrifuge tube containing
Isolyte S, pH 7.4 (Braun/McGaw Pharmaceuticals). The cells
were centrifuged (1000 rpm/7 min), the supernatant discarded
and the process repeated. After the final wash, viability of cells was
assessed using the 0.4% trypan blue dye exclusion method prior to
and following transplantation. Transplant cell concentrations were
adjusted for each group, respectively: 100,000 cells/ml, 250,000
cells/ml and 500,000 cells/ml.
Surgery
The MNC hUCB cells were delivered intravenously in mice
under anesthesia with Isofluorane (2–5% at 2L O2/min) as
previously described [31]. Briefly, the jugular vein was exposed
and isolated using blunt dissection. The vein was ligated and a
small hole made with a 26 gauge needle. A 31 gauge needle
attached to a 100 ml Hamilton syringe was placed into the lumen
of the vein and sutured in place. The cells (10610
6,2 5 610
6, and
50610
6) in 100 ml of Media (Isolyte S, pH 7.4) were delivered over
5 min. The Media mouse group received 100 ml of Isolate S, the
same volume administered to cell transplant mice. The needle was
withdrawn, the suture tightened and the incision closed. All
animals, excluding the hTgn and C57BL/6 groups, were
immunosuppressed with CsA (10 mg/kg ip per day) during the
post-transplantation period.
Characteristics of disease progression
The evaluation of animal disease progression was previously
described [31,41,42]. All measures of disease progression were
performed blind by independent investigators to avoid subjective
bias. Body weight was measured weekly throughout the study.
Extension reflex and rotorod test were observed one week prior to
transplant, at 12, 14, and 16 weeks of age, and then weekly until
20 weeks of age. After the last behavioral test, lifespan was
determined.
Extension Reflex. The mouse was suspended by the tail and
extension of each hindlimb observed. If the mouse showed normal
hindlimb extension, a score of 2 was given. A score of 1 indicated
partial hindlimb extension. If no extension was observed, the score
was 0.
Rotorod. The mouse was placed on a 3.2 cm diameter axle
rotating at a speed of 16 rpm (Omnitech Rotoscan). The latency
(sec) that the mouse stayed on the rotating axle during a 3 minute
period was counted.
Tissue preparation
The criterion for euthanatization was decreased body weight
(more than 10 %) and the inability of mice to move and reach food
and/or water due to hindlimb paralysis and muscle atrophy.
When progression of disease symptoms reached the point of
paralysis, half of the mice from each group receiving 10610
6,
25610
6,5 0 610
6 MNC hUCB cells, Media, CsA, or C57 BL/6
were sacrificed under deep chloral hydrate (10%) anesthesia and
perfused transcardially with 4% paraformaldehyde (PFA) in 0.1 M
phosphate buffer (PB, pH 7.2). The cervical and lumbar segments
of the spinal cord were removed, post-fixed, and then cryopro-
tected in 20% sucrose in 0.1 M PB overnight. Coronal sections
(30 mm) were cut in a cryostat, thaw-mounted on slides, and stored
at 20uC for immunohistochemical analysis. The other half of these
mice and all hTgn mice were sacrificed under deep anesthesia,
then the brain, spinal cord, and spleen were removed. Weight of
the spleen was measured. The brain regions (brainstem, motor
cortex) and lumbar spinal cord segment were dissected and frozen
in liquid nitrogen and stored at 220uC for cytokine assay. Part of
the spleen was cut and also frozen following storage at 220uC.
Additionally, blood samples were obtained from all animals. About
300 ml of blood was taken transcardially and collected into blood
collection tubes with EDTA (K3) (Sherwood Medical, MO). Blood
smears were made from snips of the animal tails and then fixed
with Methanol for 4–6 min and stored at 220uC. Analyses for
Cell Blood Count (CBC) and White Blood Cell (WBC) differential
were performed by Antech Diagnostics (NY, USA). Samples of
plasma were collected and FAST Quant microspot assay for
human Th1/Th2 Cytokines (IL-1 b, TNF a, INF c, IL-2, IL-4,
IL-5, IL-6, IL10, and IL-13) was performed by Schleicher &
Schuell BioScience, Inc. (Keene, NH, USA) using manufacturer’s
protocol. Plasma samples from hUCB (n=10) were used as
controls. Quantitative results of cytokines were presented as
picogram per milliliter.
Ribonuclease extraction and Ribonuclease Protection
Assay
Ribonuclease Protection Assay (RPA) was performed as
previously described [43]. Briefly, total RNA from homogenized
tissues was extracted using Qiagen Rneasy minikit (Qiagen,
Valencia, CA) according to the manufacturer `s instructions.
Twenty mg of total RNA from each sample was hybridized with
antisense, radiolabeled probes, after which free probe and
remaining single-stranded RNA were digested with RNase A/
T1. Double-stranded RNase-protected fragments were resolved on
5% denaturing polyacrylamide gels. The probe template used was
purchased from Pharmingen (San Diego, CA) and included mouse
specific sequences for interleukin-1 a (IL-1 a), interleukin-1 b (IL-1
b), tumor necrosis factor a (TNF a) tumor necrosis factor b (TNF
b). Additionally, a custom mouse template for IL-2 and IL-10 was
used for the spleen. A positive control transcript was made using a
probe specific for the ribosomal protein L32, housekeeping gene,
in order to calculate the specific activity and achieve a sufficient
excess of probe over target for L32. L32 probe was then added to
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transfer RNA and rat mRNA were used as negative and positive
controls, respectively. Dried gels were placed on a phosphorimager
screen for 16 –20 hours. The phosphorimaging screen was
subsequently scanned with a phosphorimager (Molecular Image
System GS-363; Bio-Rad, Hercules, CA). The images were
processed using Molecular Analyst software (Bio-Rad). The
intensity of a band in the computer generated image is directly
proportional to the amount of radioactivity within the band. The
optical density (OD) values obtained from each band were
normalized against the OD obtained from the L32 band in that
sample by the following expression: (OD of the sample band / OD
of the L32 band X 100).
Splenic lymphocyte proliferation assay
The proliferation rate of splenic lymphocytes from G93A mice
treated with different MNC hUCB cell doses was studied using the
CyQUANT Cell Proliferation Assay Kit (Molecular Probes,
Invitogen) based on green-fluorescent CyQUANT GR dye, which
exhibits strong fluorescent enhancement when bound to cellular
nucleic acids. The spleens were aseptically removed from mice
(n=5/group) and disrupted by passage through a sterile plastic
strainer. Spleen cell suspensions were prepared in RPMI 1640 and
then resuspended in same media containing 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 10 mg/ml of gentamicin and 50 mM2 -
mercaptoethanol. The cells were counted with a V-cell hematolog-
ical counter (Beckman Coulter) and plated on a 96 well plate at a
density of 2.5610
4 cells/well. The phytohemagglutinin (PHA) was
then added in 10 mg/ml doses. The culture medium was removed
after cultivation for 72 hours and cells were frozen in the plate at
270uC until samples were assayed. After thawing the plates
containing the cells at RT, 200 ml of green-fluorescent CyQUANT
GR dye/cell lysis buffer was added for 5 min. The fluorescent
enhancement was measured with excitation at 485 nm and emission
at 530 nm using a Multi-Detection Microplate Reader. Index of
stimulation was calculated as the ratio between induced PHA
proliferation and spontaneous division of splenocytes.
Immunohistochemistry
Immunohistochemical staining of microglial cells in the
spinal cord. Serial sections of the cervical and lumbar spinal
cord were rinsed several times in PBS to remove the freezing
medium. The tissues were incubated in a solution of 40%
Methanol and 30% H2O2 in PBS for 20 min at RT and then
placed in a blocking solution of 10% normal goat serum (NGS)
and 0.3% Triton X-100 in PBS for 60 min at RT. Then the tissues
were incubated with rabbit polyclonal anti-Iba1 antibody (1:2000,
Wako), 3% NGS, and 0.3% Triton X-100 in PBS overnight at
4uC. After incubation, the slides were rinsed in PBS and incubated
with biotinylated goat-anti-rabbit secondary antibody (1:500,
Vector Laboratories), 3% NGS, and 0.3% Triton X-100 in PBS
for 60 min at RT. After several rinses in PBS, an avidin-biotin-
peroxidase (ABC-Elite kit, Vector) with 3,3-diaminobenzidine
(DAB, Pierce) were used to verify microglia/macrophages within
the spinal cords. Tissues were then coverslipped with Permount
and examined under a microscope.
Immunohistochemical staining of MNC hUCB cells in the
spinal cord and blood smears. For identification of the MNC
hUCB cells in the cervical/lumbar spinal cords and blood smears,
staining with the human-specific marker (HuNu) as we described
previously [31]. Briefly, the mouse monoclonal antibody (HuNu,
1:50, Chemicon) was combined with the secondary antibody,
monovalent goat anti mouse Fab’ fragment conjugated to FITC
(1:200; Jackson Immunoresearch). Prior to applying this antibody
cocktail, which had been previously incubated for 60 min at RT,
on the slides, M.O.M. immunodetection kit (Vector) was used
according to manufacturer’s protocol to eliminate the fluorescein
background staining. After blocking the tissue with M.O.M.
blocking solution and 5% normal human serum (NHS) for 60 min
at RT, the antibody complex was applied to the tissues and
incubated for 60 min at RT. After a few rinses in PBS, the spinal
cord sections were double stained for Nestin (1:200; Chemicon)
overnight at 4uC. Next day, the slides were incubated for 2 hrs
with appropriate secondary antibodies conjugated to rhodamine
(1:1200, Alexa, Molecular Probes). The sections were coverslipped
with Vectashield with DAPI (Vector Laboratories) and examined
under epifluorescence using an Olympus BX60 microscope. For
blood smears, the immunostaining procedure only for HuNu, as
described above, was used.
Microglial cell count
Analysis of microglial cell density was performed using a
computerized image analysis program (Image-Pro Plus, Media
Cybernetics, Inc., Silver Springs, MD). Briefly, measurements of
cervical/lumbar ventral horn area were first performed by
determining the cross-point of a line passing the central canal
perpendicular to the midline. Volume of ventral gray matter was
determined below this line in the right and left cervical/lumbar
spinal cords in coronal sections (n=4–5/slide) from each mouse
group (n=3–4/group) at predetermined uniform intervals
(90 mm). Number of microglial cells was counted within ventral
gray matter of cervical/lumbar spinal cords. Density of microglial
cells was determined as cell number per mm. Data is presented as
average of cell density of both sides.
Statistics
Data are presented as means6S.E.M. One-way ANOVA with
Student-Newman-Keuls Multiple Comparison test was used. The
Kaplan-Meier method was used to determine the difference in
survival rate between the groups of G93A mice with or without
cell transplants and is reported as a chi-squared value (x2).
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